Use access key #2 to skip to page content.

AndrewGreenBull (97.68)

XNPT is on the move

Recs

2

November 05, 2009 – Comments (1) | RELATED TICKERS: GSK , TEVA , ABT

FDA is expected to make a decision on Monday of XNPT's lead candidate XP13512.

XNPT is hit by widen loss, but once the company's leading drug is approved, it will recover for sure.

We see a positive signal today, and i believe the upward trend will keep moving until market close on Friday. Let's see how far it will go tomorrow.

* Statement: The author of this article is not a licensed analyst and
the purpose of this article is for information sharing and discussion
only, not recommendation for any stock buying, selling and shorting
activities. Please do your own research before making any trading
decision.

1 Comments – Post Your Own

#1) On November 05, 2009 at 11:03 PM, AndrewGreenBull (97.68) wrote:

Some facts about XNPT's lead candidate XP13512(from 10-Q P9):

In February 2007, the Company entered into an exclusive collaboration with GSK to develop and commercialize XP13512 in all countries of the world excluding the Astellas territory (collectively referred to as the GSK territory). In March 2007, GSK made an up-front, non-refundable license payment of $75,000,000. In addition, GSK has agreed to make additional payments of:

 (i) up to $275,000,000 upon the achievement of additional clinical and regulatory milestones, of which $85,000,000 has been received to date, including a milestone payment of $20,000,000 received in March 2009; and

(ii) up to $290,000,000 upon the achievement of specified XP13512 sales levels. Under the terms of the agreement, GSK is responsible for all future development costs and GSK is solely responsible for the manufacturing of XP13512 to support its development and commercialization within the GSK territory.

Report this comment

Featured Broker Partners